A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Cytochrome P450 2C19 (CYP2C19) is clinically important for the metabolism of many therapeutic drugs. CYP2C19 has two main point mutation sites leading to low metabolic capacity. Several CYP enzymes are also important for the metabolism of chemical carcinogens, and several studies have reported associations between CYP polymorphism and cancer susceptibility. Speculating on a potential association between CYP2C19 polymorphism and cancer susceptibility, we conducted this study in two phases. Cell lines of various gastroenterological cancers were screened in the first phase. A clinical investigation was then conducted to confirm the association with the candidate cancer in the second phase.
Genetic polymorphism of CYP2C19 was investigated in a total of 114 cell lines of five gastroenterological cancers. Based on this screening investigation suggesting an association with biliary tract cancer, we conducted a related study by recruiting 65 patients with biliary tract cancer and 566 patients with benign diseases as controls.
Among the 114 cell lines investigated, biliary tract cancer was suggested to be most strongly associated with poor metabolizers of CYP2C19. Among 65 patients with biliary tract cancer, 18 (28%) were poor metabolizers of CYP2C19, whereas 87 (15%) of 566 control patients were poor metabolizers. The age- and gender-adjusted odds ratios for intermediate and poor metabolizers regarding the risk of biliary tract cancer were 1.5 (95% CI: 0.8–3.0, P = 0.17) and 2.7 (1.3–5.9, P = 0.006) compared to extensive metabolizers.
A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
- Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther. 1993;266:52–9.
- Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit. 1994;16:214–5.
- Ieiri, I, Kubota, T, Urae, A, Kimura, M, Wada, Y, Mamiya, K (1996) Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59: pp. 647-653 CrossRef
- Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348–55.
- Skjelbo, E, Brosen, K, Hallas, J, Gram, LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49: pp. 18-23 CrossRef
- Ward, SA, Walle, T, Walle, UK, Wilkinson, GR, Branch, RA (1989) Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 45: pp. 72-79 CrossRef
- Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol. 1995;40:481–5.
- Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309–17.
- Mega, JL, Close, SL, Wiviott, SD, Shen, L, Hockett, RD, Brandt, JT (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: pp. 354-362 CrossRef
- Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60:661–6.
- De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594–8.
- de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419–22.
- Furuta, T, Ohashi, K, Kosuge, K, Zhao, XJ, Takashima, M, Kimura, M (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65: pp. 552-561 CrossRef
- Klotz, U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44: pp. 297-302
- Furuta, T, Ohashi, K, Kamata, T, Takashima, M, Kosuge, K, Kawasaki, T (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129: pp. 1027-1030
- Jeurissen, SM, Bogaards, JJ, Boersma, MG, ter Horst, JP, Awad, HM, Fiamegos, YC (2006) Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethyleugenol. Chem Res Toxicol 19: pp. 111-116 CrossRef
- Degawa, M (1995) Chemical carcinogenesis and cytochrome P450: carcinogenic aromatic amine-induced P450 and hepatocarcinogenic susceptibility to the aromatic amine in the rodent. Yakugaku Zasshi 115: pp. 1-14
- Shi, WX, Chen, SQ (2004) Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol 10: pp. 1961-1963
- Roddam, PL, Rollinson, S, Kane, E, Roman, E, Moorman, A, Cartwright, R (2000) Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10: pp. 605-615 CrossRef
- Sugimoto, M, Furuta, T, Shirai, N, Nakamura, A, Kajimura, M, Sugimura, H (2005) Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol Ther 22: pp. 1033-1040 CrossRef
- Nagahashi, M, Ajioka, Y, Lang, I, Szentirmay, Z, Kasler, M, Nakadaira, H (2008) Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. World J Gastroenterol 14: pp. 70-75 CrossRef
- Yamamoto, M, Haga, M, Takagi, S, Endoh, K, Ito, S, Yoshida, K (1990) HLA antigens in cancer of the gallbladder. Tohoku J Exp Med 161: pp. 69-71 CrossRef
- Sheth, S, Bedford, A, Chopra, S (2000) Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol 95: pp. 1402-1410 CrossRef
- WHO (2006) Mortality database. http://www.who.int/healthinfo/morttables/en/index.html
- Serra, I, Yamamoto, M, Calvo, A, Cavada, G, Baez, S, Endoh, K (2002) Association of chili pepper consumption, low socioeconomic status and longstanding gallstones with gallbladder cancer in a Chilean population. Int J Cancer 102: pp. 407-411 CrossRef
- Xie HG. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci. 2000;66:PL175–81.
- Xie, HG, Kim, RB, Stein, CM, Wilkinson, GR, Wood, AJ (1999) Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br J Clin Pharmacol 48: pp. 402-408 CrossRef
- Yamamoto, S (2000) Biliary tract cancer mortality rates by prefectures in Japan. Jpn J Clin Oncol 30: pp. 576
- Adachi, Y (1994) Changes in the concentrations of chlornitrofen (CNP) and CNP-amino in river and faucet water in Niigata, Japan. Nippon Eiseigaku Zasshi 48: pp. 1090-1098
- Kawajiri, K, Nakachi, K, Imai, K, Yoshii, A, Shinoda, N, Watanabe, J (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 263: pp. 131-133 CrossRef
- Drakoulis, N, Cascorbi, I, Brockmoller, J, Gross, CR, Roots, I (1994) Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 72: pp. 240-248 CrossRef
- Shi, X, Zhou, S, Wang, Z, Zhou, Z (2008) CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer 59: pp. 155-163 CrossRef
- Uematsu, F, Ikawa, S, Kikuchi, H, Sagami, I, Kanamaru, R, Abe, T (1994) Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 4: pp. 58-63 CrossRef
- Aktas, D, Guney, I, Alikasifoglu, M, Yuce, K, Tuncbilek, E, Ayhan, A (2002) CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 86: pp. 124-128 CrossRef
- Nimura, Y, Yokoyama, S, Fujimori, M, Aoki, T, Adachi, W, Nasu, T (1997) Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer 80: pp. 852-857 CrossRef
- Lin, DX, Tang, YM, Peng, Q, Lu, SX, Ambrosone, CB, Kadlubar, FF (1998) Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 7: pp. 1013-1018
- Murata, M, Watanabe, M, Yamanaka, M, Kubota, Y, Ito, H, Nagao, M (2001) Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165: pp. 171-177 CrossRef
- Hayashi, SI, Watanabe, J, Nakachi, K, Kawajiri, K (1991) PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res 19: pp. 4797 CrossRef
- Marchand, LL, Wilkinson, GR, Wilkens, LR (1999) Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 8: pp. 495-500
- A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer
Journal of Gastroenterology
Volume 45, Issue 10 , pp 1045-1052
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Biliary tract cancer
- Genetic polymorphism
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
- 2. Department of Gastroenterology, Sanno Hospital, 8-10-16 Akasaka, Minato-Ku, Tokyo, 107-0052, Japan
- 3. Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanasi, 400-8506, Japan